Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The macrolide-bacterium interaction and its biological basis.

Robert C Goldman1, Franco Scaglione

  • 1Department of Health and Human Services, National Institute of Allergy and Infectious Diseases, Division of AIDS, Bethesda, MD 20892, USA. rgoldman@niaid.nih.gov

Current Drug Targets. Infectious Disorders
|September 24, 2004
PubMed
Summary

Erythromycin and its successors, macrolide antibiotics, have evolved significantly over 50 years to combat bacterial resistance. Newer macrolides, like ketolides, overcome common resistance mechanisms such as ribosomal modification and efflux pumps.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem.

Infectious disorders drug targets·2018
Same author

Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Tuberculosis (Edinburgh, Scotland)·2013
Same author

Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosis.

Infectious disorders drug targets·2011
Same author

Maximizing bactericidal activity with combinations of bioreduced drugs.

Future medicinal chemistry·2011
Same author

Antituberculosis activity of the molecular libraries screening center network library.

Tuberculosis (Edinburgh, Scotland)·2009
Same author

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Tuberculosis (Edinburgh, Scotland)·2009

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Pharmacology

Background:

  • Erythromycin, the first macrolide antibiotic, has been used for over 50 years to treat various bacterial infections.
  • Macrolide antibiotics have undergone significant chemical evolution, leading to improved generations like acylides and ketolides.
  • Bacterial resistance, primarily through ribosomal RNA modification (MLS resistance) and active efflux, poses a major clinical challenge.

Purpose of the Study:

  • To review the chemical evolution of macrolide antibiotics.
  • To explore the development of macrolides that overcome common resistance mechanisms.
  • To highlight the advancements leading to the ketolide class.

Main Methods:

  • Review of historical development and chemical modifications of macrolides.

Related Experiment Videos

  • Analysis of structure-activity relationships concerning bacterial resistance mechanisms.
  • Examination of medicinal chemistry strategies to design novel macrolide analogs.

    • Main Results:

    • Structural modifications have been key to improving macrolide efficacy against resistant bacteria.
    • Development of macrolides that can bind to modified ribosomes and evade efflux pumps has been achieved.
    • The ketolide class represents a significant advancement, combining resistance to efflux and partial restoration of ribosome binding.

    Conclusions:

    • Medicinal chemistry has successfully engineered macrolides to overcome key bacterial resistance mechanisms.
    • Ketolides offer a promising therapeutic option by addressing both ribosomal modification and efflux-mediated resistance.
    • Continued chemical evolution of macrolides is crucial for combating evolving bacterial resistance.